|Drug Patent Number||Company||Drug Patent Title||Drug Patent Expiry||Activity Alert|
|These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).|
|US7700128||TAKEDA PHARMS USA||Solid preparation comprising an insulin sensitizer, an insulin secretagogue and a polyoxyethylene sorbitan fatty acid ester|| |
(3 years from now)
|US8071130||TAKEDA PHARMS USA||Solid preparation|| |
(4 years from now)
Duetact is owned by Takeda Pharms Usa.
Duetact contains Glimepiride; Pioglitazone Hydrochloride.
Duetact has a total of 2 drug patents out of which 0 drug patents have expired.
Duetact was authorised for market use on 28 July, 2006.
Duetact is available in tablet;oral dosage forms.
The generics of Duetact are possible to be released after 08 June, 2028.
Market Authorisation Date: 28 July, 2006
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic